News and Developments - Xylonix

news and developments

Press Releases

Xylonix Secures Exclusive Distribution Rights for Invitrocue’s Onco-PDO and ADPS Cancer Diagnostics in Korea and Japan

[29 July 2025]

“The partnership will deliver Real-Time Cancer Adaptive Program to cancer patients across Korea and Japan”

Invitrocue and Genecast bring Real-time Personalized Adaptive Treatment to Cancer patients

[17 June 2025]

“Combining Onco-PDO and Ultrasenstive ADPS delivers unmatched Precision, Ultra-sensitive Detection, and is Fast and Accessible”

Xylonix and LysinBio to Combat Disease X of Bacterial Origin

[18 November 2024]

“…to focus beyond viruses – readying for deadlier bacterial Disease X with super antibacterials and nasal sprays”

Xylonix and Genecast to Transform Cancer Metastasis Research

[31 October 2024]

“New Ultra-Sensitive Blood Test to Accelerate Metastasis Studies from Months to Weeks”

Xylonix Study Reveals Link Between COVID-19 and Non-COVID-19 Excess Deaths

[December 2023]

“…up to 76% of the Non-COVID-19 excess deaths could be explained by Long COVID-patterns.”

Duke-NUS, Xylonix to improve effectiveness of Xylonix cancer drugs

[October 2021]

“New drug formulations aim to improve the in vivo circulation of Xylonix’s novel immunotherapies for treating both cancer and complications arising from COVID-19 infection.”